{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T20:51:14Z","timestamp":1763326274983,"version":"3.45.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CUF Academic Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although upper tract urothelial carcinoma (UTUC) and bladder urothelial carcinoma (BUC) share histological features, they differ in clinical behavior and management. Valid adjuvant options include surveillance, platinum-based chemotherapy, and immune checkpoint inhibitors (ICIs). To assess real-world practice, we conducted a survey among Portuguese medical oncologists dedicated to genitourinary malignancies, exploring their preferences for adjuvant therapy in high-risk UTUC (illustrated as pT2N1M0) across three clinical scenarios that differed by PD-L1 status and renal function. Among 34 respondents, cisplatin plus gemcitabine was the preferred regimen in cisplatin-eligible patients, regardless of PD-L1 status (94% in PD-L1-negative and 85% in PD-L1-positive tumors). In PD-L1-positive, cisplatin-ineligible patients, carboplatin plus gemcitabine was preferred (47%), followed by ICIs (44%). These findings suggest a consistent preference for platinum-based chemotherapy, likely reflecting UTUC-specific evidence from the POUT trial and apparent limited ICI benefit in this subgroup, underscoring the need for dedicated prospective trials.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf365","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:27:25Z","timestamp":1761744445000},"source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant treatment preferences in high-risk upper tract urothelial carcinoma: the perspective of Portuguese medical oncologists"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6464-4575","authenticated-orcid":false,"given":"Guilherme","family":"Vilhais","sequence":"first","affiliation":[{"name":"CUF Oncology Hematology and Oncology Department, , Lisbon 1350-352,","place":["Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio","family":"Fontes-Sousa","sequence":"additional","affiliation":[{"name":"CUF Oncology Hematology and Oncology Department, , Lisbon 1350-352,","place":["Portugal"]},{"name":"ULS Lisboa Ocidental Medical Oncology Department, , Lisbon 1449-005,","place":["Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2025111615472284700_oyaf365-B1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025111615472284700_oyaf365-B2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"key":"2025111615472284700_oyaf365-B3","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.3390\/cancers15235558","article-title":"Clinical and biological differences between upper tract carcinoma and bladder urothelial cancer, including implications for clinical practice","volume":"15","author":"Lefort","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025111615472284700_oyaf365-B4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"2025111615472284700_oyaf365-B5","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"2025111615472284700_oyaf365-B6","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.23.01659","article-title":"Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the POUT trial","volume":"42","author":"Birtle","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111615472284700_oyaf365-B7","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"2025111615472284700_oyaf365-B8","doi-asserted-by":"crossref","first-page":"LBA531","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA531","article-title":"AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation","volume":"42","author":"Apolo","year":"2024","journal-title":"JCO"},{"key":"2025111615472284700_oyaf365-B9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025111615472284700_oyaf365-B10","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1016\/j.ejca.2009.06.016","article-title":"Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients","volume":"45","author":"Lughezzani","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025111615472284700_oyaf365-B11","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025111615472284700_oyaf365-B12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf365\/65041841\/oyaf365.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf365\/65041841\/oyaf365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf365\/65041841\/oyaf365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T20:47:29Z","timestamp":1763326049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf365\/8306832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf365","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,30]]},"article-number":"oyaf365"}}